Tony Mok

Giannis Mountzios: Tony Mok Presented Herthena – Lung 03 With Patritumab DXd vs PBC in EGFR Mutation NSCLC at ASCO25

Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:

“Tony Mok presenting Herthena -Lung 03 with patritumab DXd vs PBC in patients with EGFR mutation NSCLC
  • Modest PFS benefit HR=0.77, mPFS 5,8 vs 5.4
  •  ORR 35.2 vs 25.3, including CNS ( NS)
  •  No OS benefit
  •  ILD=5.2%”

Giannis Mountzios: Tony Mok Presented Herthena - Lung 03 With Patritumab DXd vs PBC in EGFR Mutation NSCLC at ASCO25

More posts featuring Giannis Mountzios.

ASCO25 cancer Giannis Mountzios OncoDaily Oncology PATRITUMAB Tony Mok